Clinical trial
A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
NCT02235272 is registered in ClinicalTrials.gov with Xigen SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
- Lead sponsor
- Xigen SA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- December 31, 2015
- Enrollment
- 339 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.